Company Filing History:
Years Active: 2005
Title: Hakan Nyqvist: Innovator in Pharmaceutical Chemistry
Introduction
Hakan Nyqvist is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for medical use. His work has implications for the treatment of central nervous system disorders.
Latest Patents
Hakan Nyqvist holds a patent for "Tartrate salts of (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide." This patent describes a new salt, specifically the (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen tartrate. The patent details the processes for manufacturing this tartrate salt, its use in medicine, and its application in pharmaceutical formulations. Furthermore, it outlines a method for treating CNS disorders by administering the tartrate salt to patients in need.
Career Highlights
Hakan Nyqvist is currently employed at AstraZeneca AB, a leading global biopharmaceutical company. His role involves research and development in the field of drug formulation and delivery. His innovative approach has contributed to the advancement of therapeutic options available for various medical conditions.
Collaborations
Hakan collaborates with Daniel Sohn, a fellow researcher at AstraZeneca AB. Together, they work on projects that aim to enhance the efficacy and safety of pharmaceutical compounds.
Conclusion
Hakan Nyqvist's contributions to pharmaceutical chemistry, particularly through his patent on tartrate salts, highlight his role as an innovator in the field. His work continues to influence the development of new treatments for CNS disorders, showcasing the importance of innovation in medicine.